To test the efficacies of pharmacological inhibition of CREBZF in the attenuation of obesity‐associated inflammation and insulin resistance, we adapted a luciferase assay to a high‐throughput screening (HTS) strategy for identifying potential compounds that repress the transcription of CREBZF (Figure 6A). Here, CREBZF is linked to obesity due to melanocortin 4 receptor deficiency.